secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2024-06-13T23:59:59+00:00
Accession:  0001104659-24-071048
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Therapeutics appoints Nathan Jorgensen as CFO effective July 8, 2024
----------------------------------------------------------------------------

- Jorgensen, 47, previously CFO of Vor Biopharma; will report to CEO Alfred Sandrock.
- Annual base salary of $480,000; target annual bonus of 40% of base salary.
- Inducement equity grants: option to purchase 200,000 shares (4-year vest) and RSU for 80,000 shares (3-year vest).
- Severance: 12 months base salary plus pro-rata bonus and COBRA on termination without cause or for good reason within 12 months of a sale event.
- Employment at-will; standard non-compete and non-solicitation provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000110465924071048/0001104659-24-071048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000110465924071048/tm2417027d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-071048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer